manilatimes13h
Full-Year 2024 Results - Progress on the implementation of the FOCUS-27 plan driven by enhanced effectiveness and financial discipline
Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only ...
Medpage Today on MSN15h
Seasonal Allergies on the Rise?
Among racial and ethnic groups, non-Hispanic white adults reported the highest rate of seasonal allergies (28.4%), followed ...
VALBIOTIS SA: Valbiotis unveils its annual financial statements and confirms its strategic and financial goals
Valbiotis unveils its annual financial statements and confirms its strategic and financial goals VALBIOTIS SA VALBIOTIS SA: Valbiotis unveils its annual financial statements and confirms ...
Hosted on MSN12h
The New Treatment Landscape in Seasonal Allergies
Recent developments in allergen immunotherapy, improvements in primary care, and the emergence of a new treatment for other ...
snmjournals.org15h
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)
Following the Food and Drug Administration’s approval of Lutathera and Pluvicto in 2018 and 2022, respectively, we predicted ...
Stellantis proposes two new board members to boost tech expertise, financial oversight
Carmaker Stellantis has nominated Daniel Ramot and Alice Schroeder as new board members, as well as proposing the re-election ...
Stellantis proposes new American directors for European-centric board
The automaker wants to add Alice Schroeder and Daniel Ramot to its 11-seat board of directors, a shift toward North America.
The Pharma Letter12h
EFPIA has its say on Critical Medicines Act
The Critical Medicines Alliance Strategic Report has been published in a bid to develop a coordinated, European industrial ...
Stellantis proposes new board additions for tech and financial expertise
European carmaker Stellantis (NYSE:STLA) has proposed two new board members, Daniel Ramot and Alice Schroeder, to enhance its ...
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant ...
DRI Healthcare Trust Reports Fourth Quarter and Annual 2024 Results
CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the fourth quarter and year ...